AER-01 is a lead therapeutic candidate designed to dissolve mucus plugs in the airways of patients with severe respiratory diseases. Developed through extensive academic collaborations, it is an inhaled thiol-saccharide mucolytic agent intended to improve lung function and ease breathing difficulties.